Increased plasma adiponectin closely associates with vascular endothelial dysfunction in type 2 diabetic patients...

Several studies found that adiponectin, an adipokine withstands atherosclerosis in vivo, is significantly increased in subjects with diabetic nephropathy (DN), but its clinical meaning remains unclear. For its structural similarity to complement C1q and collagen, we performed this study to explore the relationship between adiponectin and the vascular endothelial function alterations in DN patients. 50 type 2 diabetic patients without clinical cardiovascular complications were assigned to control group, microalbuminuria group (Micro-MA), and macroalbuminuria group (Macro-MA) according to the Mogensen's criteria. Plasma adiponectin and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected. Flow-mediated dilatation (FMD), nitroglycerin-induced dilatation (NID) and cardiologic parameters were measured by ultrasound cardiogram. Plasma adiponectin level was significantly and gradually increased in agreement with the amount of urine albumin excretion. sVCAM-1 was higher in Micro-MA and Macro-MA patients than in the controls, but it was comparable between the former 2 groups. FMD and NID were both remarkably decreased in Macro-MA group compared with Micro-MA and control group. For the whole subjects, plasma adiponectin was negatively related to FMD (r=-0.397, P<0.01) and NID (r=-0.413, P<0.01). These results suggest that increased plasma adiponectin may predict co-existing vascular endothelial dysfunction in DN patients.